Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 3.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 26,258 shares of the biopharmaceutical company’s stock after purchasing an additional 962 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Celldex Therapeutics were worth $1,041,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Kynam Capital Management LP boosted its stake in Celldex Therapeutics by 23.1% in the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after acquiring an additional 600,000 shares during the period. Wellington Management Group LLP raised its position in shares of Celldex Therapeutics by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after purchasing an additional 300,406 shares during the period. Eventide Asset Management LLC lifted its holdings in shares of Celldex Therapeutics by 16.1% in the 3rd quarter. Eventide Asset Management LLC now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $44,032,000 after purchasing an additional 222,260 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Celldex Therapeutics by 18.6% during the 3rd quarter. Rock Springs Capital Management LP now owns 500,101 shares of the biopharmaceutical company’s stock valued at $13,763,000 after purchasing an additional 78,486 shares during the period. Finally, SG Americas Securities LLC grew its stake in Celldex Therapeutics by 1,481.7% during the 3rd quarter. SG Americas Securities LLC now owns 78,011 shares of the biopharmaceutical company’s stock worth $2,147,000 after buying an additional 73,079 shares during the last quarter.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $37.77 on Wednesday. Celldex Therapeutics, Inc. has a 1 year low of $22.11 and a 1 year high of $53.18. The firm has a market capitalization of $2.11 billion, a PE ratio of -12.98 and a beta of 1.50. The stock has a fifty day moving average of $42.11 and a two-hundred day moving average of $36.08.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CLDX shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, April 17th. Finally, Guggenheim boosted their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.